← Issue №6/ week of Aug 9, 2026/Hepatology

Shear wave elastography demonstrates similar risk stratification performance to vibration-controlled transient elastography in FIB-4-based two-step algorithms for MASLD.

From GI Signals issue №6: what this paper found, what it changes, and where it sits against the current standard of care, reviewed by Simon Mathews, MD.

Hepatology prospective cohort · n=2,817 · Aug 14, 2026 · Hepatology · IF 18.0

Shear wave elastography demonstrates similar risk stratification performance to vibration-controlled transient elastography in FIB-4-based two-step algorithms for MASLD.

New evidenceMASLDbiomarker
Clinical takeawaySWE demonstrated similar performance to VCTE for MASLD risk stratification. If SWE is available at your institution, this study supports its use as an alternative to VCTE. If your institution is implementing an elastography program and choosing between modalities, either is supported by this evidence; decide based on cost, operator expertise, and availability. Ongoing VCTE use does not require change.
What it foundSWE and VCTE showed similar 60-month risk prediction for liver-related events in MASLD (time-dependent AUROC: AGA 0.770 vs 0.775, EASL 0.804 vs 0.805; no significant difference between modalities).
ContextThis prospective cohort study validates SWE against hard clinical endpoints (liver-related events) in MASLD, showing similar risk stratification performance to VCTE and establishing SWE as a viable alternative modality.
No standard claimed for this paper

Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.

Lee J … Lee SK · Hepatology · IF 18.0 · PubMed ↗Permalink
← Read the whole of issue №6 Every paper GI Signals surfaces gets a page like this one. All issues